J&J exhibited additional findings, displaying that nipocalimab met its key secondary endpoint, a change in QMG score.

Johnson & Johnson JNJ on Tuesday announced results from additional analyses of the Phase 3 Vivacity-MG3 study and the ongoing ...

Johnson & Johnson announced results from additional analyses of the Phase 3 Vivacity-MG3 double-blind study and the ongoing open-label ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension ...

“The Phase 3 Vivacity-MG3 data demonstrates our steadfast pursuit of researching and developing potential innovative and ...

The filing is supported by data from the phase III Vivacity-MG3 study, gMG is an autoantibody-driven neuromuscular disease marked by fluctuating muscle weakness. Besides gMG and SjD, J&J is also ...

Johnson & Johnson announced compelling results from its Phase 3 Vivacity-MG3 study on nipocalimab, showing promising efficacy and safety in treating generalized myasthenia gravis, which were ...

On 8 April, at the 2025 American Academy of Neurology (AAN) meeting, Johnson & Johnson (J&J) announced results from additional analyses of the Phase III Vivacity-MG3 double-blind study and the ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension ...